Congenital Hyperinsulinism Clinical Trial
— GLP-1-CHIOfficial title:
The Physiology of Glucagon-like-peptide-1 Espression in Patients With Endogenous Hyperinsulinism: Correlation With Histopathology
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | February 1, 2019 |
Est. primary completion date | February 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 16 Years |
Eligibility |
Inclusion Criteria: - Biochemically and clinically proven endogenous congenital hyperinsulinism: - Unresponsive to medical treatment (diazoxide) - Indication for 18F-DOPA PET/CT based on mutation analysis - Standard imaging (18F-DOPA PET/CT) not older than 8 weeks - <16 years old - Informed consent signed by parents or legal guardians of the patient. Exclusion Criteria: - Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous ABCC8/KCNJ11 mutation) - Calculated creatinine clearance below 40 ml/min - Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions based on CT) - Age > 16 years - No signed informed consent |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboudumc | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University | Charite University, Berlin, Germany, European Commission, Helsinki University, Turku University Hospital, University College, London, University Hospital Inselspital, Berne, University Hospital, Basel, Switzerland, University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Expression and distribution of GLP-1R in pancreas of children with CHI | Comparison of PET quantification with autoradiography and histology | 1 year | |
Secondary | Comparison of the exendin PET/CT and F-DOPA PET/CT | Comparison of sensitivity and specificity for localization of focal CHI | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
Recruiting |
NCT04732416 -
HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
|
Phase 2 | |
Completed |
NCT02937558 -
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
|
Phase 2 | |
Completed |
NCT02604485 -
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
|
Phase 2 | |
Recruiting |
NCT04205604 -
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
|
Phase 2 | |
Completed |
NCT00897676 -
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
|
Phase 1/Phase 2 | |
Completed |
NCT00987168 -
Sandostatine® LP and Hyperinsulinism
|
Phase 2 | |
Active, not recruiting |
NCT03941236 -
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
|
Phase 3 | |
Completed |
NCT03042416 -
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
|
Phase 3 | |
Completed |
NCT04172441 -
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
|
Phase 2/Phase 3 | |
Recruiting |
NCT04706910 -
18F-DOPA II - PET Imaging Optimization
|
Phase 3 | |
Recruiting |
NCT06208215 -
RZ358 Treatment for Congenital Hyperinsulinism
|
Phase 3 | |
Completed |
NCT03777176 -
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
|
Phase 3 | |
Completed |
NCT04538989 -
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
|
Phase 2 | |
Completed |
NCT01070758 -
Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
|
Phase 4 | |
Completed |
NCT00674440 -
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
|
Phase 2 | |
Terminated |
NCT00835328 -
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
|
Phase 1/Phase 2 | |
Completed |
NCT00571324 -
Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03053284 -
Pasireotide in Hyperinsulinemic Hypoglycemia
|
Phase 2 | |
No longer available |
NCT02835131 -
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
|